Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Over-expression of CLN3P, the Batten disease protein, inhibits PANDER-induced apoptosis in neuroblastoma cells: further evidence that CLN3P has anti-apoptotic properties.

Narayan SB, Rakheja D, Pastor JV, Rosenblatt K, Greene SR, Yang J, Wolf BA, Bennett MJ.

Mol Genet Metab. 2006 Jun;88(2):178-83. Epub 2006 Mar 3.

PMID:
16515873
2.

Juvenile neuronal ceroid-lipofuscinosis (Batten disease): a brief review and update.

Rakheja D, Narayan SB, Bennett MJ.

Curr Mol Med. 2007 Sep;7(6):603-8. Review.

PMID:
17896996
3.

CLN3p impacts galactosylceramide transport, raft morphology, and lipid content.

Rusyn E, Mousallem T, Persaud-Sawin DA, Miller S, Boustany RM.

Pediatr Res. 2008 Jun;63(6):625-31. doi: 10.1203/PDR.0b013e31816fdc17.

PMID:
18317235
4.

CLN3L, a novel protein related to the Batten disease protein, is overexpressed in Cln3-/- mice and in Batten disease.

Narayan SB, Pastor JV, Mitchison HM, Bennett MJ.

Brain. 2004 Aug;127(Pt 8):1748-54. Epub 2004 Jul 7.

PMID:
15240430
5.

Characterization of Cln3p, the gene product responsible for juvenile neuronal ceroid lipofuscinosis, as a lysosomal integral membrane glycoprotein.

Ezaki J, Takeda-Ezaki M, Koike M, Ohsawa Y, Taka H, Mineki R, Murayama K, Uchiyama Y, Ueno T, Kominami E.

J Neurochem. 2003 Dec;87(5):1296-308.

6.

The Batten disease gene product (CLN3p) is a Golgi integral membrane protein.

Kremmidiotis G, Lensink IL, Bilton RL, Woollatt E, Chataway TK, Sutherland GR, Callen DF.

Hum Mol Genet. 1999 Mar;8(3):523-31.

PMID:
9949212
7.

Amlodipine prevents apoptotic cell death by correction of elevated intracellular calcium in a primary neuronal model of Batten disease (CLN3 disease).

Warnock A, Tan L, Li C, An Haack K, Narayan SB, Bennett MJ.

Biochem Biophys Res Commun. 2013 Jul 12;436(4):645-9. doi: 10.1016/j.bbrc.2013.04.113. Epub 2013 Jun 13.

PMID:
23769828
8.

Screening for calcium channel modulators in CLN3 siRNA knock down SH-SY5Y neuroblastoma cells reveals a significant decrease of intracellular calcium levels by selected L-type calcium channel blockers.

An Haack K, Narayan SB, Li H, Warnock A, Tan L, Bennett MJ.

Biochim Biophys Acta. 2011 Feb;1810(2):186-91. doi: 10.1016/j.bbagen.2010.09.004. Epub 2010 Oct 7.

9.

Biosynthesis and intracellular targeting of the CLN3 protein defective in Batten disease.

Järvelä I, Sainio M, Rantamäki T, Olkkonen VM, Carpén O, Peltonen L, Jalanko A.

Hum Mol Genet. 1998 Jan;7(1):85-90.

PMID:
9384607
10.

Defective intracellular transport of CLN3 is the molecular basis of Batten disease (JNCL)

Järvelä I, Lehtovirta M, Tikkanen R, Kyttälä A, Jalanko A.

Hum Mol Genet. 1999 Jun;8(6):1091-8. Erratum in: Hum Mol Genet 1999 Aug;8(8):1585.

PMID:
10332042
11.

CLN3 protein is targeted to neuronal synapses but excluded from synaptic vesicles: new clues to Batten disease.

Luiro K, Kopra O, Lehtovirta M, Jalanko A.

Hum Mol Genet. 2001 Sep 15;10(19):2123-31.

PMID:
11590129
12.

Altered arginine metabolism in the central nervous system (CNS) of the Cln3-/- mouse model of juvenile Batten disease.

Chan CH, Ramirez-Montealegre D, Pearce DA.

Neuropathol Appl Neurobiol. 2009 Apr;35(2):189-207. doi: 10.1111/j.1365-2990.2008.00984.x.

PMID:
19284480
13.

The CLN3 gene is a novel molecular target for cancer drug discovery.

Rylova SN, Amalfitano A, Persaud-Sawin DA, Guo WX, Chang J, Jansen PJ, Proia AD, Boustany RM.

Cancer Res. 2002 Feb 1;62(3):801-8.

14.

CLN3P, the Batten's disease protein, is a novel palmitoyl-protein Delta-9 desaturase.

Narayan SB, Rakheja D, Tan L, Pastor JV, Bennett MJ.

Ann Neurol. 2006 Nov;60(5):570-7.

PMID:
17036287
15.

Retinal pathology and function in a Cln3 knockout mouse model of juvenile Neuronal Ceroid Lipofuscinosis (batten disease).

Seigel GM, Lotery A, Kummer A, Bernard DJ, Greene ND, Turmaine M, Derksen T, Nussbaum RL, Davidson B, Wagner J, Mitchison HM.

Mol Cell Neurosci. 2002 Apr;19(4):515-27.

PMID:
11988019
16.

Investigation of Batten disease with the yeast Saccharomyces cerevisiae.

Pearce DA, Sherman F.

Mol Genet Metab. 1999 Apr;66(4):314-9.

PMID:
10191120
17.

Defective lysosomal arginine transport in juvenile Batten disease.

Ramirez-Montealegre D, Pearce DA.

Hum Mol Genet. 2005 Dec 1;14(23):3759-73. Epub 2005 Oct 26.

PMID:
16251196
18.

Drafting the CLN3 protein interactome in SH-SY5Y human neuroblastoma cells: a label-free quantitative proteomics approach.

Scifo E, Szwajda A, Dębski J, Uusi-Rauva K, Kesti T, Dadlez M, Gingras AC, Tyynelä J, Baumann MH, Jalanko A, Lalowski M.

J Proteome Res. 2013 May 3;12(5):2101-15. doi: 10.1021/pr301125k. Epub 2013 Apr 19. Erratum in: J Proteome Res. 2013 Aug 2;12(8):3822.

PMID:
23464991
19.

CLN3P, the Batten disease protein, localizes to membrane lipid rafts (detergent-resistant membranes).

Rakheja D, Narayan SB, Pastor JV, Bennett MJ.

Biochem Biophys Res Commun. 2004 May 14;317(4):988-91.

PMID:
15094366
20.

Studies of pH regulation by Btn1p, the yeast homolog of human Cln3p.

Pearce DA, Nosel SA, Sherman F.

Mol Genet Metab. 1999 Apr;66(4):320-3.

PMID:
10191121

Supplemental Content

Support Center